X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs STERLING BIOTECH - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. STERLING BIOTECH FRESENIUS KABI ONCO./
STERLING BIOTECH
 
P/E (TTM) x 22.1 -1.8 - View Chart
P/BV x 3.1 0.1 4,415.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   STERLING BIOTECH
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
STERLING BIOTECH
Dec-13
FRESENIUS KABI ONCO./
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs17611 1,676.2%   
Low Rs793 2,308.8%   
Sales per share (Unadj.) Rs37.726.8 140.6%  
Earnings per share (Unadj.) Rs5.1-15.0 -34.1%  
Cash flow per share (Unadj.) Rs6.7-5.5 -123.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.554.9 77.5%  
Shares outstanding (eoy) m158.23267.87 59.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,302.4%   
Avg P/E ratio x25.0-0.5 -5,376.8%  
P/CF ratio (eoy) x18.9-1.3 -1,487.7%  
Price / Book Value ratio x3.00.1 2,361.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,862 1,081.5%   
No. of employees `0001.21.4 85.1%   
Total wages/salary Rs m703547 128.6%   
Avg. sales/employee Rs Th5,176.25,303.3 97.6%   
Avg. wages/employee Rs Th610.4403.8 151.2%   
Avg. net profit/employee Rs Th699.6-2,959.0 -23.6%   
INCOME DATA
Net Sales Rs m5,9637,181 83.0%  
Other income Rs m1843 42.3%   
Total revenues Rs m5,9817,223 82.8%   
Gross profit Rs m1,430947 151.0%  
Depreciation Rs m2582,543 10.1%   
Interest Rs m-264,377 -0.6%   
Profit before tax Rs m1,216-5,931 -20.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-1,924 -17.8%   
Profit after tax Rs m806-4,007 -20.1%  
Gross profit margin %24.013.2 181.9%  
Effective tax rate %28.132.4 86.7%   
Net profit margin %13.5-55.8 -24.2%  
BALANCE SHEET DATA
Current assets Rs m5,10214,335 35.6%   
Current liabilities Rs m2,38549,809 4.8%   
Net working cap to sales %45.6-494.0 -9.2%  
Current ratio x2.10.3 743.1%  
Inventory Days Days150403 37.2%  
Debtors Days Days113171 66.4%  
Net fixed assets Rs m5,14855,432 9.3%   
Share capital Rs m158268 59.1%   
"Free" reserves Rs m6,55613,935 47.0%   
Net worth Rs m6,73214,701 45.8%   
Long term debt Rs m9529,478 10.0%   
Total assets Rs m10,38873,988 14.0%  
Interest coverage x-45.8-0.4 12,896.3%   
Debt to equity ratio x0.10.6 21.9%  
Sales to assets ratio x0.60.1 591.5%   
Return on assets %7.50.5 1,498.9%  
Return on equity %12.0-27.3 -43.9%  
Return on capital %14.6-6.4 -227.3%  
Exports to sales %74.525.9 287.5%   
Imports to sales %24.80.2 14,582.8%   
Exports (fob) Rs m4,4411,860 238.8%   
Imports (cif) Rs m1,47712 12,109.8%   
Fx inflow Rs m5,2981,860 284.8%   
Fx outflow Rs m1,77225 7,120.1%   
Net fx Rs m3,5251,835 192.1%   
CASH FLOW
From Operations Rs m1,2741,719 74.1%  
From Investments Rs m-1,204-3,148 38.3%  
From Financial Activity Rs m-1961,426 -13.8%  
Net Cashflow Rs m-126-3 3,714.7%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 9.6 9.9 97.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 9.1 39.3 23.2%  
Shareholders   42,599 21,482 198.3%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS